• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向 NLRP3 炎性小体的基因编辑治疗炎症性疾病。

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases.

机构信息

Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 510006, Guangzhou, Guangdong, China.

National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, 510006, Guangzhou, Guangdong, China.

出版信息

Nat Commun. 2018 Oct 5;9(1):4092. doi: 10.1038/s41467-018-06522-5.

DOI:10.1038/s41467-018-06522-5
PMID:30291237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6173702/
Abstract

The NLRP3 inflammasome is a well-studied target for the treatment of multiple inflammatory diseases, but how to promote the current therapeutics remains a large challenge. CRISPR/Cas9, as a gene editing tool, allows for direct ablation of NLRP3 at the genomic level. In this study, we screen an optimized cationic lipid-assisted nanoparticle (CLAN) to deliver Cas9 mRNA (mCas9) and guide RNA (gRNA) into macrophages. By using CLAN encapsulating mCas9 and gRNA-targeting NLRP3 (gNLRP3) (CLAN), we disrupt NLRP3 of macrophages, inhibiting the activation of the NLRP3 inflammasome in response to diverse stimuli. After intravenous injection, CLAN mitigates acute inflammation of LPS-induced septic shock and monosodium urate crystal (MSU)-induced peritonitis. In addition, CLAN treatment improves insulin sensitivity and reduces adipose inflammation of high-fat-diet (HFD)-induced type 2 diabetes (T2D). Thus, our study provides a promising strategy for treating NLRP3-dependent inflammatory diseases and provides a carrier for delivering CRISPR/Cas9 into macrophages.

摘要

NLRP3 炎性小体是治疗多种炎症性疾病的研究热点,但如何促进现有治疗方法的发展仍然是一个巨大的挑战。CRISPR/Cas9 作为一种基因编辑工具,可以在基因组水平上直接靶向 NLRP3 进行基因敲除。在本研究中,我们筛选了一种优化的阳离子脂质体辅助纳米颗粒(CLAN),以将 Cas9 mRNA(mCas9)和靶向 NLRP3 的指导 RNA(gRNA)递送至巨噬细胞。通过使用封装 mCas9 和靶向 NLRP3 的 gRNA(gNLRP3)的 CLAN(CLAN),我们破坏了巨噬细胞中的 NLRP3,抑制了其对各种刺激的反应性激活。静脉注射后,CLAN 减轻了 LPS 诱导的脓毒症休克和单钠尿酸盐晶体(MSU)诱导的腹膜炎的急性炎症。此外,CLAN 治疗改善了高脂肪饮食(HFD)诱导的 2 型糖尿病(T2D)患者的胰岛素敏感性并减少了脂肪组织炎症。因此,我们的研究为治疗 NLRP3 依赖性炎症性疾病提供了一种有前途的策略,并为将 CRISPR/Cas9 递送至巨噬细胞提供了一种载体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/751149477038/41467_2018_6522_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/6651763ba4d1/41467_2018_6522_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/1a7a6003912b/41467_2018_6522_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/5017bea6dfbe/41467_2018_6522_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/7cf8f430779a/41467_2018_6522_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/2d021afaa949/41467_2018_6522_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/4af1d4e7e831/41467_2018_6522_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/751149477038/41467_2018_6522_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/6651763ba4d1/41467_2018_6522_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/1a7a6003912b/41467_2018_6522_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/5017bea6dfbe/41467_2018_6522_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/7cf8f430779a/41467_2018_6522_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/2d021afaa949/41467_2018_6522_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/4af1d4e7e831/41467_2018_6522_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/6173702/751149477038/41467_2018_6522_Fig7_HTML.jpg

相似文献

1
Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases.靶向 NLRP3 炎性小体的基因编辑治疗炎症性疾病。
Nat Commun. 2018 Oct 5;9(1):4092. doi: 10.1038/s41467-018-06522-5.
2
ARIH2 Ubiquitinates NLRP3 and Negatively Regulates NLRP3 Inflammasome Activation in Macrophages.ARIH2使NLRP3泛素化并负向调节巨噬细胞中NLRP3炎性小体的激活。
J Immunol. 2017 Nov 15;199(10):3614-3622. doi: 10.4049/jimmunol.1700184. Epub 2017 Oct 11.
3
Ablation of Neuropilin 1 in Myeloid Cells Exacerbates High-Fat Diet-Induced Insulin Resistance Through Nlrp3 Inflammasome In Vivo.髓系细胞中神经纤毛蛋白1的缺失通过Nlrp3炎性小体在体内加剧高脂饮食诱导的胰岛素抵抗。
Diabetes. 2017 Sep;66(9):2424-2435. doi: 10.2337/db17-0132. Epub 2017 Jun 28.
4
Oxidized phosphatidylcholine induces the activation of NLRP3 inflammasome in macrophages.氧化磷脂酰胆碱诱导巨噬细胞中NLRP3炎性小体的激活。
J Leukoc Biol. 2017 Jan;101(1):205-215. doi: 10.1189/jlb.3VMA1215-579RR. Epub 2016 Jun 2.
5
Vascular endothelial cells senescence is associated with NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation via reactive oxygen species (ROS)/thioredoxin-interacting protein (TXNIP) pathway.血管内皮细胞衰老与通过活性氧(ROS)/硫氧还蛋白相互作用蛋白(TXNIP)途径激活含NOD样受体家族pyrin结构域3(NLRP3)炎性小体有关。
Int J Biochem Cell Biol. 2017 Mar;84:22-34. doi: 10.1016/j.biocel.2017.01.001. Epub 2017 Jan 4.
6
Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement.小檗碱通过触发巨噬细胞自噬抑制棕榈酸酯诱导的NLRP3炎性小体激活:小檗碱与胰岛素抵抗改善相关的新机制。
Biomed Pharmacother. 2017 May;89:864-874. doi: 10.1016/j.biopha.2017.03.003. Epub 2017 Mar 6.
7
Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice.核受体亚家族 1 组 D 成员 1 调节 NLRP3 炎症小体的昼夜节律活性,以减轻小鼠暴发性肝炎的严重程度。
Gastroenterology. 2018 Apr;154(5):1449-1464.e20. doi: 10.1053/j.gastro.2017.12.019. Epub 2017 Dec 24.
8
Trimethylamine-N-Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3-SOD2-mtROS Signaling Pathway.三甲基胺 N-氧化物通过 SIRT3-SOD2-mtROS 信号通路激活 NLRP3 炎性小体诱导血管炎症。
J Am Heart Assoc. 2017 Sep 4;6(9):e006347. doi: 10.1161/JAHA.117.006347.
9
Juniperus rigida Sieb. extract inhibits inflammatory responses via attenuation of TRIF-dependent signaling and inflammasome activation.杜松提取物通过减弱TRIF依赖性信号传导和炎性小体激活来抑制炎症反应。
J Ethnopharmacol. 2016 Aug 22;190:91-9. doi: 10.1016/j.jep.2016.05.059. Epub 2016 May 31.
10
Flavonoids interfere with NLRP3 inflammasome activation.黄酮类化合物会干扰NLRP3炎性小体的激活。
Toxicol Appl Pharmacol. 2018 Sep 15;355:93-102. doi: 10.1016/j.taap.2018.06.022. Epub 2018 Jun 28.

引用本文的文献

1
Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy.疾病中的损伤相关分子模式(DAMPs):对治疗的启示
Mol Biomed. 2025 Aug 29;6(1):60. doi: 10.1186/s43556-025-00305-3.
2
Mannosylated neutrophil vesicles targeting macrophages alleviate liver inflammation by delivering CRISPR/Cas9 RNPs.靶向巨噬细胞的甘露糖基化中性粒细胞囊泡通过递送CRISPR/Cas9核糖核蛋白减轻肝脏炎症。
Theranostics. 2025 May 8;15(13):6221-6235. doi: 10.7150/thno.107791. eCollection 2025.
3
Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment.

本文引用的文献

1
Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA induces homology-directed DNA repair.纳米颗粒递送Cas9核糖核蛋白和供体DNA可诱导同源定向DNA修复。
Nat Biomed Eng. 2017;1:889-901. doi: 10.1038/s41551-017-0137-2. Epub 2017 Oct 2.
2
A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.单次给药的 CRISPR/Cas9 脂质纳米颗粒实现了体内基因组编辑的强大和持久效果。
Cell Rep. 2018 Feb 27;22(9):2227-2235. doi: 10.1016/j.celrep.2018.02.014.
3
Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses.
功能化壳聚糖作为CRISPR-Cas9在癌症治疗中的纳米递送平台。
Asian J Pharm Sci. 2025 Jun;20(3):101041. doi: 10.1016/j.ajps.2025.101041. Epub 2025 Feb 26.
4
Recent Advances in mRNA Delivery Systems for Cancer Therapy.用于癌症治疗的mRNA递送系统的最新进展
Adv Sci (Weinh). 2025 Aug;12(29):e17571. doi: 10.1002/advs.202417571. Epub 2025 May 20.
5
NLRP3 Inflammasome in Vascular Dementia: Regulatory Mechanisms, Functions, and Therapeutic Implications: A Comprehensive Review.血管性痴呆中的NLRP3炎性小体:调控机制、功能及治疗意义:综述
CNS Neurosci Ther. 2025 May;31(5):e70403. doi: 10.1111/cns.70403.
6
The changes of NLRs family members in the brain of AD mouse model and AD patients.AD小鼠模型和AD患者大脑中NLRs家族成员的变化。
Front Immunol. 2025 Feb 24;16:1555124. doi: 10.3389/fimmu.2025.1555124. eCollection 2025.
7
NLRP3 inflammasome in health and disease (Review).健康与疾病中的NLRP3炎性小体(综述)
Int J Mol Med. 2025 Mar;55(3). doi: 10.3892/ijmm.2025.5489. Epub 2025 Jan 24.
8
Oxidative Stress and the NLRP3 Inflammasome: Focus on Female Fertility and Reproductive Health.氧化应激与NLRP3炎性小体:聚焦女性生育能力与生殖健康
Cells. 2025 Jan 2;14(1):36. doi: 10.3390/cells14010036.
9
Improving the use of CRISPR/Cas9 gene editing machinery as a cancer therapeutic tool with the help of nanomedicine.借助纳米医学提高CRISPR/Cas9基因编辑机制作为癌症治疗工具的应用效果。
3 Biotech. 2025 Jan;15(1):17. doi: 10.1007/s13205-024-04186-1. Epub 2024 Dec 19.
10
Biomaterials for in situ cell therapy.用于原位细胞治疗的生物材料。
BMEmat. 2023 Sep;1(3). doi: 10.1002/bmm2.12039. Epub 2023 Jul 19.
使用重组腺相关病毒简化小鼠胚胎的体外和体内基因组编辑。
Nat Commun. 2018 Jan 29;9(1):412. doi: 10.1038/s41467-017-02706-7.
4
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing.基于结构的引导RNA化学修饰可实现高效的非病毒体内基因组编辑。
Nat Biotechnol. 2017 Dec;35(12):1179-1187. doi: 10.1038/nbt.4005. Epub 2017 Nov 13.
5
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.鉴定一种用于治疗炎症性疾病的选择性直接NLRP3抑制剂。
J Exp Med. 2017 Nov 6;214(11):3219-3238. doi: 10.1084/jem.20171419. Epub 2017 Oct 11.
6
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.使用mRNA纳米载体对治疗性细胞毒性试剂进行肇事逃逸式编程。
Nat Commun. 2017 Aug 30;8(1):389. doi: 10.1038/s41467-017-00505-8.
7
CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation.氯离子细胞内通道蛋白(CLICs)依赖性氯离子外流是NLRP3炎性小体激活的一个重要且直接的上游事件。
Nat Commun. 2017 Aug 4;8(1):202. doi: 10.1038/s41467-017-00227-x.
8
Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo.可生物降解的氨基酸酯纳米材料用于 Cas9 mRNA 的体内外递送。
ACS Appl Mater Interfaces. 2017 Aug 2;9(30):25481-25487. doi: 10.1021/acsami.7b08163. Epub 2017 Jul 19.
9
CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.基于 CRISPR/Cas9 的基因组编辑在疾病建模和治疗中的应用:非病毒递送的挑战和机遇。
Chem Rev. 2017 Aug 9;117(15):9874-9906. doi: 10.1021/acs.chemrev.6b00799. Epub 2017 Jun 22.
10
Unexpected mutations after CRISPR-Cas9 editing in vivo.体内CRISPR-Cas9编辑后出现的意外突变。
Nat Methods. 2017 May 30;14(6):547-548. doi: 10.1038/nmeth.4293.